Skip to content

{ Tag Archives } Aviv Stock

Can-Fite Initiates Preparatory Work For Psoriasis Phase III Trial With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to [...]

Bookmark and Share Also tagged , , , , , , , , , , , ,
2009 10 01 Skin Care News Comments Off

Can-Fite-Completed Patient Enrollment For The Phase II Trial In Psoriasis With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another goal by completion of patients’ enrollment in its phase II Psoriasis trial. Approximately 70 patients were enrolled to this study, randomized into 4 groups treated with 1, 2 and 4 mg of CF101 and placebo. Patients are taking [...]

Bookmark and Share Also tagged , , , , , , , , , ,
2009 06 02 Skin Care News Comments Off